JP2011026326A5 - - Google Patents

Download PDF

Info

Publication number
JP2011026326A5
JP2011026326A5 JP2010200674A JP2010200674A JP2011026326A5 JP 2011026326 A5 JP2011026326 A5 JP 2011026326A5 JP 2010200674 A JP2010200674 A JP 2010200674A JP 2010200674 A JP2010200674 A JP 2010200674A JP 2011026326 A5 JP2011026326 A5 JP 2011026326A5
Authority
JP
Japan
Prior art keywords
group
alkyl
hydrogen
alkylcarbonyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010200674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011026326A (ja
Filing date
Publication date
Priority claimed from US10/079,324 external-priority patent/US20030158188A1/en
Priority claimed from US10/364,210 external-priority patent/US7074805B2/en
Application filed filed Critical
Publication of JP2011026326A publication Critical patent/JP2011026326A/ja
Publication of JP2011026326A5 publication Critical patent/JP2011026326A5/ja
Pending legal-status Critical Current

Links

JP2010200674A 2002-02-20 2010-09-08 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物 Pending JP2011026326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/079,324 US20030158188A1 (en) 2002-02-20 2002-02-20 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US10/364,210 US7074805B2 (en) 2002-02-20 2003-02-11 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003569203A Division JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Publications (2)

Publication Number Publication Date
JP2011026326A JP2011026326A (ja) 2011-02-10
JP2011026326A5 true JP2011026326A5 (https=) 2011-11-24

Family

ID=27759931

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003569203A Expired - Fee Related JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物
JP2010200674A Pending JP2011026326A (ja) 2002-02-20 2010-09-08 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003569203A Expired - Fee Related JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Country Status (8)

Country Link
EP (1) EP1478363B1 (https=)
JP (2) JP4614662B2 (https=)
AT (1) ATE420644T1 (https=)
CA (1) CA2476936A1 (https=)
DE (1) DE60325834D1 (https=)
ES (1) ES2319886T3 (https=)
MX (1) MXPA04008073A (https=)
WO (1) WO2003070247A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316777T3 (es) * 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003251828A1 (en) * 2002-07-12 2004-02-02 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7375126B2 (en) 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
PT2017265E (pt) * 2003-06-12 2011-07-29 Abbott Lab Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1)
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
CA2743534A1 (en) * 2003-08-05 2005-02-24 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
JP4935073B2 (ja) * 2003-10-14 2012-05-23 味の素株式会社 エーテル誘導体
WO2005040100A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
EP1685112B1 (en) * 2003-11-08 2011-07-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives as vr1 antagonists
KR101042490B1 (ko) 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(vr1)활성 저해제
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
JP2009534399A (ja) * 2006-04-18 2009-09-24 アボット・ラボラトリーズ バニロイド受容体サブタイプ1型(vr1)の拮抗薬およびその使用
TW200824687A (en) 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
WO2008079683A2 (en) 2006-12-20 2008-07-03 Abbott Laboratories N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
JP2010520875A (ja) 2007-03-09 2010-06-17 レノビス, インコーポレイテッド P2x7調節因子としてのビシクロヘテロアリール化合物およびその使用
CA2683461A1 (en) * 2007-04-16 2008-10-23 Gruenenthal Gmbh Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
DE102007018149A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2323989A4 (en) 2008-03-20 2011-06-22 Abbott Lab METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
EP2264031B1 (en) 2008-04-18 2015-04-15 Daewoong Pharmaceutical Co., Ltd. A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
EP2435407B1 (en) * 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
WO2015091965A2 (en) * 2013-12-19 2015-06-25 Lanxess Deutschland Gmbh Process for the production of phthalimides
CN113413387A (zh) * 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
CN105906564B (zh) * 2016-05-05 2018-11-30 海南省药物研究所 化合物、制备方法及其用途
UA124884C2 (uk) 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
US10696638B2 (en) * 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043694A (en) * 1960-05-23 1962-07-10 Eastman Kodak Co Novel class of 3-indazolinone developing agent
FR1344579A (fr) * 1961-11-23 1963-11-29 Sandoz Sa Nouveaux dérivés de l'indole et leur préparation
JPS5587771A (en) * 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
DE3430310A1 (de) * 1984-08-15 1986-02-27 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue dopamin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS62116559A (ja) * 1985-11-18 1987-05-28 Sagami Chem Res Center 4−アシルメチリデン−4,5,6,7−テトラヒドロインド−ル誘導体及びその製造方法
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
HU210581B (en) * 1990-03-07 1995-05-29 Rhone Poulenc Rorer Sa Process for prep. of glycinamide deriv.s and pharmaceutical compn.s contg. them
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
JPH1087629A (ja) * 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
HK1042472B (zh) * 1999-02-22 2005-12-09 Medifron Dbt Co., Ltd. 作爲有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物,其组合物以及应用
JP2001122895A (ja) * 1999-10-20 2001-05-08 Hamari Chemicals Ltd 新規なオピオイドペプチド誘導体
HUP0301493A2 (hu) * 2000-03-09 2003-08-28 Ono Pharmaceutical Co., Ltd. Indolszármazékok, eljárás előállításukra és alkalmazásuk
WO2001098269A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2004525071A (ja) * 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
JP2004339061A (ja) * 2001-09-28 2004-12-02 Takeda Chem Ind Ltd ベンゼン誘導体、その製造法および用途
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
GB0130550D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
JP2003192659A (ja) * 2001-12-26 2003-07-09 Bayer Ag フェニル尿素誘導体
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Similar Documents

Publication Publication Date Title
JP2011026326A5 (https=)
IL186349A0 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
IL221573A (en) Imidazoquinolines and their use in the preparation of drugs for the treatment of proliferative and inflammatory and obstructive pulmonary diseases
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
IL181049A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
JP2007077157A5 (https=)
CY2016040I2 (el) Επιλογες θεραπειας για τη νοσο του fabry
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
AP2006003671A0 (en) Sulfonamide derivatives for the treatment of diseases
JP2011057678A5 (https=)
JP2011526924A5 (https=)
IL206039A0 (en) Pharmaceutically acceptable salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate and their use in therapy
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
JP2010525056A5 (https=)
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
PL1817282T3 (pl) Pochodne kwasu fenoksyoctowego użyteczne do leczenia chorób układu oddechowego
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
JP2006528617A5 (https=)
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
EP1729786A4 (en) ADMINISTRATION OF CISPLATIN BY INHALATION
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
JP2008502694A5 (https=)